Market›Health Care›Biotechnology›Biotechnology
INHIBIKASE THERAPEUT Equity

IKT

$1.88Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$226M
MVM
-$2.6M
TD Variance
-0.500

Every news event mapped to its market reaction — 70 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2022-11-07-39.2%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2024-04-19-34.8%newsSeeking AlphaInhibikase Therapeutics files to sell common stock, warrants
2025-02-18+30.5%legalSEC EDGARIKT 8-K: 5.02, 7.01 (SEC Filing)
2025-01-29-30.5%legalSEC EDGARIKT 8-K: 8.01 (SEC Filing)
2022-03-08+28.0%legalSEC EDGARIKT 8-K: 5.02 and (SEC Filing)
2021-06-16-27.8%legalSEC EDGARIKT 8-K: 1.01 and (SEC Filing)
2023-01-26-24.8%legalSEC EDGARIKT 8-K: 1.01, 1.02, 3.02, 7.01 (SEC Filing)
2025-02-24-23.6%legalSEC EDGARIKT 8-K: 1.01, 3.02, 5.02, 7.01 (SEC Filing)
2023-01-25-23.1%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2024-02-01-17.8%legalSEC EDGARIKT 8-K: 1.01 and (SEC Filing)
2024-10-10+16.2%legalSEC EDGARIKT 8-K: 1.01, 3.02, 5.02, 7.01, 8.01 (SEC Filing)
2022-11-17+16.2%legalSEC EDGARIKT 8-K: 2.02 and (SEC Filing)
2024-11-14-13.4%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17
2024-04-30-13.2%legalSEC EDGARIKT 8-K: 7.01, 8.01 (SEC Filing)
2024-05-16-13.0%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.73
2024-10-22+10.4%legalSEC EDGARIKT 8-K: 1.01, 5.02, 7.01 (SEC Filing)
2024-06-18-10.0%newsSeeking AlphaInhibikase Therapeutics files to sell 4.76M shares of common stock for holders
2025-05-14-9.6%legalSEC EDGARIKT 8-K: 2.02 and (SEC Filing)
2025-04-14-8.9%executiveSeeking AlphaInhibikase Therapeutics appoints David McIntyre as CFO; shares rise
2025-04-14-8.9%legalSEC EDGARIKT 8-K: 5.02, 7.01 (SEC Filing)
2024-05-20+8.9%newsSeeking AlphaInhibikase Therapeutics prices its direct offering, warrant inducement
2024-05-20+8.9%legalSEC EDGARIKT 8-K: 1.01, 3.02, 7.01 (SEC Filing)
2024-10-09+8.7%newsSeeking AlphaInhibikase Therapeutics stock rises after pricing $110M private offering
2024-02-07-8.6%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2023-08-15-7.7%earningsSeeking AlphaInhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
2025-05-02-7.6%newsSeeking AlphaInhibikase Therapeutics: A Hold With Uncertain Prospects In PAH
2024-05-18+7.4%earningsSeeking AlphaInhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
2023-07-17-6.8%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2026-03-26+6.5%newsGlobeNewswireInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
2026-03-26+6.5%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.49
2026-03-26+6.5%legalSEC EDGARIKT 8-K: 2.02 and (SEC Filing)
2024-03-27-6.5%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line
2025-05-15-6.3%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.15
2024-03-28-5.9%earningsSeeking AlphaInhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
2026-04-07-5.4%newsMT NewswiresInhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension
2026-04-07-5.4%newsGlobeNewswireInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
2024-01-16+4.7%legalSEC EDGARIKT 8-K: 5.02 and (SEC Filing)
2023-06-29-4.5%newsSeeking AlphaInhibikase Therapeutics will effect 1-for-6 reverse stock split
2023-08-14-4.3%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$1.11 misses by $0.19, revenue of $116.41M
2024-08-15-4.2%earningsSeeking AlphaInhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
2024-08-15-4.2%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01
2025-11-14-4.1%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.13
2025-11-14-4.1%legalSEC EDGARIKT 8-K: 2.02 and (SEC Filing)
2025-11-20-3.9%newsSeeking AlphaInhibikase Therapeutics announces proposed public offering and pre-funded warrants
2025-11-20-3.9%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2023-11-15-3.4%earningsSeeking AlphaInhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call Transcript
2026-02-22+3.3%newsTipRanksBank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2024-11-18-3.2%legalSeeking AlphaInhibikase Therapeutics files for secondary offering of common stock
2025-06-20-2.8%legalSeeking AlphaInhibikase Therapeutics files $300M mixed securities shelf
2026-02-18+2.7%newsMotley FoolSands Capital Opens $10 Million ServiceTitan Position
2025-08-14+2.6%legalSEC EDGARIKT 8-K: 2.02, 7.01 (SEC Filing)
2022-03-21-2.5%legalSEC EDGARIKT 8-K: 5.02 and (SEC Filing)
2022-09-01-2.5%legalSEC EDGARIKT 8-K: 5.02, 7.01 (SEC Filing)
2022-05-17-2.1%legalSEC EDGARIKT 8-K: 1.01 and (SEC Filing)
2023-03-06-2.0%legalSEC EDGARIKT 8-K: 5.02 (SEC Filing)
2025-03-27-1.9%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$1.16
2025-03-27-1.9%legalSEC EDGARIKT 8-K: 2.02 and (SEC Filing)
2023-11-14-1.8%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.86
2025-12-19-1.8%legalSEC EDGARIKT 8-K: 8.01 and (SEC Filing)
2024-01-17-1.5%executiveSeeking AlphaInhibikase Therapeutics appoints Lees-Rolfe as CFO
2026-03-04-1.2%newsMT NewswiresLadenburg Thalmann Initiates Inhibikase Therapeutics at Buy
2025-11-21-1.2%newsSeeking AlphaInhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share
2025-11-21-1.2%legalSEC EDGARIKT 8-K: 1.01, 8.01 (SEC Filing)
2026-04-03-1.0%newsGlobeNewswireInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-18-1.0%newsSeeking AlphaInhibikase Therapeutics receives Nasdaq compliance
2023-03-13+0.9%legalSEC EDGARIKT 8-K: 8.01 (SEC Filing)
2025-08-15+0.8%earningsSeeking AlphaInhibikase Therapeutics GAAP EPS of -$0.11
2021-09-08+0.5%legalSEC EDGARIKT 8-K: 8.01 (SEC Filing)
2024-11-19+0.1%newsSeeking AlphaInhibikase: Potential To Improve Current Treatment Options For PAH Patients
2024-04-02+0.1%legalSEC EDGARIKT 8-K: 5.02 and (SEC Filing)
tickerdossier.comtickerdossier.substack.com